<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20694" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Doxazosin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kim</surname>
            <given-names>Jinhyuck</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nguyen</surname>
            <given-names>Hoang</given-names>
          </name>
          <aff>NOVA Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jinhyuck Kim declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hoang Nguyen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20694.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Doxazosin is a medication used to manage and treat benign prostatic hyperplasia, hypertension, ureteral stones, and PTSD-associated nightmares. It is a quinazoline derivative that acts as a competitive alpha1-antagonist. This activity describes the indications, action, and contraindications for doxazosin as a valuable agent in treating and managing benign prostatic hyperplasia, hypertension, ureteral stones, and PTSD-associated nightmares. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent to healthcare providers.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of doxazosin.</p></list-item><list-item><p>Describe the potential adverse effects that can accompany therapy with doxazosin.</p></list-item><list-item><p>Review disease-related concerns for which a provider must exercise caution when prescribing doxazosin.</p></list-item><list-item><p>Summarize some interprofessional team strategies for improving care coordination and communication to advance and improve outcomes using doxazosin.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20694&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20694">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20694.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Benign Prostatic Hyperplasia
<list list-type="bullet"><list-item><p>Doxazosin is an alpha1&#x000a0;antagonist that is FDA approved to treat the signs and symptoms of benign prostatic hyperplasia (BPH) or lower urinary tract symptoms (LUTS). In the USA, alpha1&#x000a0;antagonists&#x000a0;are&#x000a0;the most commonly used treatment for the&#x000a0;signs and symptoms of&#x000a0;BPH.<xref ref-type="bibr" rid="article-20694.r1">[1]</xref>&#x000a0;Though drug therapy for the management of symptoms BPH or LUTS may not be as effective as surgery, it may be sufficient for symptom management and avoid the more serious adverse effects of surgery.<xref ref-type="bibr" rid="article-20694.r2">[2]</xref></p></list-item><list-item><p>There is also an&#x000a0;extended-release formulation of doxazosin. It utilizes the gastrointestinal therapeutic system (GITS). It is FDA-approved for the treatment of BPH and LUTS but does not have approval for the treatment of hypertension. One benefit of&#x000a0;the extended-release formulation&#x000a0;is stable drug concentrations throughout the day and decreased incidence of orthostatic hypotension/syncope.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension (immediate release only)
<list list-type="bullet"><list-item><p>The immediate-release formulation can a second-line agent for the management of hypertension in patients with concomitant BPH.<xref ref-type="bibr" rid="article-20694.r3">[3]</xref>&#x000a0;If combination therapy is needed to achieve blood pressure control, the recommendation is to combine it with a diuretic for optimal effectiveness.<xref ref-type="bibr" rid="article-20694.r4">[4]</xref>&#x000a0;There is a sentiment that doxazosin can be used as monotherapy for hypertension in a patient with LUTS or BPH; however, the American Urologic Society states that monotherapy&#x000a0;with doxazosin is not optimal and hypertension should have separate management.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ureteral Stones
<list list-type="bullet"><list-item><p>The use of alpha1-antagonists, including doxazosin, for the treatment of ureteral calculi is recommended by US and European guidelines. Tamsulosin has the most evidence, but doxazosin has demonstrated efficacy in the expulsion of ureteral calculi less than 10 mm as medical therapy alone or in combination with shockwave lithotripsy.<xref ref-type="bibr" rid="article-20694.r5">[5]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>PTSD Associated Nightmares
<list list-type="bullet"><list-item><p>Like prazosin, doxazosin has an off-label use for the treatment of PTSD-associated nightmares. There have been numerous small studies and case reports that have shown that doxazosin&#x000a0;is effective in treating PTSD-related nightmares.<xref ref-type="bibr" rid="article-20694.r6">[6]</xref><xref ref-type="bibr" rid="article-20694.r7">[7]</xref><xref ref-type="bibr" rid="article-20694.r8">[8]</xref><xref ref-type="bibr" rid="article-20694.r9">[9]</xref></p></list-item><list-item><p>The benefits of doxazosin over prazosin are a longer half-life and a gastrointestinal therapeutic availability system (in the extended-release form), allowing for a more gradual absorption of the drug, thereby reducing the peak to trough concentration ratio. This characteristic permits higher initial doses without the risk of hypotension.&#x000a0;Extended-release doxazosin&#x000a0;dosing initially starts at 4 mg daily.<xref ref-type="bibr" rid="article-20694.r10">[10]</xref><xref ref-type="bibr" rid="article-20694.r11">[11]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20694.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Doxazosin&#x000a0;is a quinazoline derivative that acts as a competitive alpha1-antagonist at the post-synaptic receptor.</p>
        <p>
<bold>In Hypertension</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Doxazosin competitively inhibits post-synaptic alpha1-adrenergic receptors causing vasodilation of arterioles and veins, which results in decreased total peripheral resistance and blood pressure.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>In Benign Prostatic Hyperplasia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Symptoms of BPH are caused by mechanical or dynamic obstruction of urine flow through the urethra. Mechanical obstruction is mostly due to prostate size. Dynamic obstruction is associated with an increase in smooth muscle tone at the neck of the bladder and the prostate. Doxazosin works by blocking alpha1&#x000a0;receptors, thereby decreasing urethral resistance and improving urine flow.<xref ref-type="bibr" rid="article-20694.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20694.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Formulations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Tablet, Oral:&#x000a0;</bold>
<list list-type="bullet"><list-item><p>1 mg, 2 mg, 4 mg&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Tablet, Oral, as mesylate:&#x000a0;</bold>
<list list-type="bullet"><list-item><p>8 mg&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Tablet Extended-Release 24 Hour, Oral:&#x000a0;</bold>
<list list-type="bullet"><list-item><p>4 mg, 8 mg&#x000a0;</p></list-item><list-item><p>As with all extended-release formulations,&#x000a0;this formulation should not be crushed to pass through a nasogastric, orogastric, or PEG tube.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Dosing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Benign Prostatic Hyperplasia</bold>
<list list-type="bullet"><list-item><p>Oral Immediate Release: Initiate at 1 mg once daily. The dose may be titrated up at 1- to 2-week intervals up to a maximum dose of 8 mg once daily. This titration should take place by doubling the dose while monitoring for response and tolerability.&#x000a0;</p></list-item><list-item><p>Oral Extended Release:&#x000a0;Initiate at 4 mg once daily. The dose may be titrated up at 3- to 4-week intervals up to a maximum dose of 8 mg once daily. The clinician should titrate by doubling the dose while&#x000a0;monitoring for response and tolerability.&#x000a0;</p></list-item><list-item><p>The reinitiation of Therapy: If therapy discontinues for several days, reinitiate therapy at the initial dose and titrate according to the initial dose regimen.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hypertension</bold>
<list list-type="bullet"><list-item><p>Oral Immediate Release: Initiate at 1 mg once daily. The dose may be titrated up to 16 mg once daily; this should occur while monitoring for response and tolerability.</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20694.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Dose-related&#x000a0;Adverse Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Orthostatic hypotension/syncope can occur, especially when combined with another antihypertensive, nitrates, or a PDE-5 inhibitor.&#x000a0;
<list list-type="bullet"><list-item><p>These adverse effects occur most commonly after the initial dose or following the reinitiation of therapy; this requires patients to follow a multistep titration regimen to avoid syncope.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Common&#x000a0;Adverse Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Weakness</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Upper respiratory tract infection</p>
          </list-item>
          <list-item>
            <p>Edema</p>
          </list-item>
          <list-item>
            <p>Rhinitis</p>
          </list-item>
          <list-item>
            <p>Dyspnea</p>
          </list-item>
          <list-item>
            <p>Allergic reactions</p>
          </list-item>
        </list>
        <p>In a research study, researchers randomly assigned a total of 3,047 men were randomly assigned to groups of a placebo, doxazosin, or combination therapy with finasteride. Adverse effects of orthostatic hypotension and dizziness occurred significantly more in the groups&#x000a0;taking doxazosin and combination treatment compared&#x000a0;to the placebo group. Rates of adverse effects were reported to peak at year one during a mean duration of 4.5 years of treatment.<xref ref-type="bibr" rid="article-20694.r13">[13]</xref></p>
      </sec>
      <sec id="article-20694.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications for the use of doxazosin are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity to doxazosin or other quinazolines.</p>
          </list-item>
          <list-item>
            <p>Pregnancy
<list list-type="bullet"><list-item><p>Doxazosin is Pregnancy Category C, meaning that there is no adequate data on the safety of doxazosin in pregnant women.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20694.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Effective therapy with doxazosin for its various indications requires titration based upon response and tolerability. Open communication between patients and providers is crucial for successful treatment. Patients should receive education on the different common side effects of doxazosin, and the provider should conduct a thorough review of other medications for possible interactions, paying particular attention to other antihypertensives, nitrates, and PDE-5 inhibitors.&#x000a0;</p>
      </sec>
      <sec id="article-20694.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Reports with overdosage and toxicity with the alpha-1 antagonists, including doxazosin, remain very limited in the literature. There is a report of one case of acute doxazosin overdose in 2005.<xref ref-type="bibr" rid="article-20694.r14">[14]</xref>&#x000a0;The study found that the patient presented to the emergency department (ED) with drowsiness, decreased blood pressure, and reflex tachycardia but did not have orthostatic hypotension or any other abnormalities. This patient&#x000a0;was able to fully awaken with supportive therapy in 8 hours and was discharged 48 hours after admission to the ED.&#x000a0;Although there are limited works of literature for the toxicity of doxazosin, it appears to have low acute toxicity.</p>
      </sec>
      <sec id="article-20694.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Doxazosin may not be a drug that providers find themselves prescribing daily. However,&#x000a0;it has a few key contexts&#x000a0;where it proves to be a valuable tool for health care workers&#x000a0;in the treatment of BPH, hypertension, ureteral stones, and PTSD-associated nightmares. Doxazosin is a medication that requires titration to an effective dose and tolerance. As such, interprofessional healthcare teams need to monitor patients closely upon the initiation and titration of therapy, starting with the prescribing clinician. The extended-release formulation of doxazosin has the benefit of once-daily dosing and more stable serum concentrations. Nurses can serve as the initial point of contact for patient questions and provide initial counseling on using the drug, dosing, and what to watch for regarding possible adverse reactions. This dosing regimen reduces the incidence of orthostatic hypotension and various other adverse effects. Because doxazosin has many drug-drug interactions, it may be helpful for a pharmacist to review the different medications that a patient is on before initiating therapy. These examples of interprofessional teamwork show how such an approach can lead to improved patient outcomes with doxazosin. [Level 5]</p>
      </sec>
      <sec id="article-20694.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20694&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20694">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20694/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20694">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20694.s11">
        <title>References</title>
        <ref id="article-20694.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Black</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Naslund</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Ollendorf</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia.</article-title>
            <source>Am J Manag Care</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>4 Suppl</issue>
            <fpage>S99</fpage>
            <page-range>S99-S110</page-range>
            <pub-id pub-id-type="pmid">16551208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20694.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <collab>AUA Practice Guidelines Committee</collab>
            <article-title>AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.</article-title>
            <source>J Urol</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>170</volume>
            <issue>2 Pt 1</issue>
            <fpage>530</fpage>
            <page-range>530-47</page-range>
            <pub-id pub-id-type="pmid">12853821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20694.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>May</month>
            <day>15</day>
            <volume>71</volume>
            <issue>19</issue>
            <fpage>e127</fpage>
            <page-range>e127-e248</page-range>
            <pub-id pub-id-type="pmid">29146535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20694.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schiffrin</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lindholm</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Kenerson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Flack</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Materson</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Ram</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Cadet</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Jean-Charles</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kountz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Townsend</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Chalmers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schutte</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Bisognano</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Touyz</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Sica</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Harrap</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-26</page-range>
            <pub-id pub-id-type="pmid">24341872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20694.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gul</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Yayc&#x00131;oglu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kuzgunbay</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sar&#x00131;turk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kayra</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Ozkardes</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Do patients on alpha-blockers for the treatment of benign prostatic hyperplasia have better results after shockwave lithotripsy of urinary stones?</article-title>
            <source>J Endourol</source>
            <year>2013</year>
            <month>May</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>612</fpage>
            <page-range>612-6</page-range>
            <pub-id pub-id-type="pmid">23237326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20694.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Jong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wauben</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Huijbrechts</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Oolders</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Haffmans</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Doxazosin treatment for posttraumatic stress disorder.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-5</page-range>
            <pub-id pub-id-type="pmid">20075659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20694.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sethi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vasudeva</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Doxazosin for the treatment of nightmares: does it really work? A case report.</article-title>
            <source>Prim Care Companion CNS Disord</source>
            <year>2012</year>
            <volume>14</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">23469321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20694.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodgman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Verrico</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Holst</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thompson-Lake</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haile</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>De La Garza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raskind</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Newton</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2016</year>
            <month>May</month>
            <volume>77</volume>
            <issue>5</issue>
            <fpage>e561</fpage>
            <page-range>e561-5</page-range>
            <pub-id pub-id-type="pmid">27249080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20694.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roepke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Danker-Hopfe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Repantis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Behnia</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Otte</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Doxazosin, an &#x003b1;-1-adrenergic-receptor Antagonist, for Nightmares in Patients with Posttraumatic Stress Disorder and/or Borderline Personality Disorder: a Chart Review.</article-title>
            <source>Pharmacopsychiatry</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-31</page-range>
            <pub-id pub-id-type="pmid">27276365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20694.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koola</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Evidence for Using Doxazosin in the Treatment of Posttraumatic Stress Disorder.</article-title>
            <source>Psychiatr Ann</source>
            <year>2016</year>
            <volume>46</volume>
            <issue>9</issue>
            <fpage>553</fpage>
            <page-range>553-555</page-range>
            <pub-id pub-id-type="pmid">27667865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20694.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vashi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Puente</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meredith</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1999</year>
            <month>Nov</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>678</fpage>
            <page-range>678-87</page-range>
            <pub-id pub-id-type="pmid">10594469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20694.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roehrborn</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Schwinn</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>171</volume>
            <issue>3</issue>
            <fpage>1029</fpage>
            <page-range>1029-35</page-range>
            <pub-id pub-id-type="pmid">14767264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20694.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Meehan</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kusek</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial.</article-title>
            <source>J Urol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>195</volume>
            <issue>6</issue>
            <fpage>1825</fpage>
            <page-range>1825-9</page-range>
            <pub-id pub-id-type="pmid">26678956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20694.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Satar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sebe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Avci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yesilagac</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gokel</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Acute intoxication with doxazosin.</article-title>
            <source>Hum Exp Toxicol</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>337</fpage>
            <page-range>337-9</page-range>
            <pub-id pub-id-type="pmid">16004202</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
